These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27231203)

  • 1. Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies.
    Shaver TM; Lehmann BD; Beeler JS; Li CI; Li Z; Jin H; Stricker TP; Shyr Y; Pietenpol JA
    Cancer Res; 2016 Aug; 76(16):4850-60. PubMed ID: 27231203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.
    Lee S; Hu Y; Loo SK; Tan Y; Bhargava R; Lewis MT; Wang XS
    Proc Natl Acad Sci U S A; 2020 May; 117(18):9912-9921. PubMed ID: 32321829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
    Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study.
    Vaughn CP; Costa JL; Feilotter HE; Petraroli R; Bagai V; Rachiglio AM; Marino FZ; Tops B; Kurth HM; Sakai K; Mafficini A; Bastien RRL; Reiman A; Le Corre D; Boag A; Crocker S; Bihl M; Hirschmann A; Scarpa A; Machado JC; Blons H; Sheils O; Bramlett K; Ligtenberg MJL; Cree IA; Normanno N; Nishio K; Laurent-Puig P
    BMC Cancer; 2018 Aug; 18(1):828. PubMed ID: 30115026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
    Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
    Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
    BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel cancer gene variants and gene fusions of triple-negative breast cancers (TNBCs) reveal their molecular diversity conserved in the patient-derived xenograft (PDX) model.
    Jung J; Jang K; Ju JM; Lee E; Lee JW; Kim HJ; Kim J; Lee SB; Ko BS; Son BH; Lee HJ; Gong G; Ahn SY; Choi JK; Singh SR; Chang S
    Cancer Lett; 2018 Aug; 428():127-138. PubMed ID: 29684420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.
    Yakirevich E; Resnick MB; Mangray S; Wheeler M; Jackson CL; Lombardo KA; Lee J; Kim KM; Gill AJ; Wang K; Gowen K; Sun J; Miller VA; Stephens PJ; Ali SM; Ross JS; Safran H
    Clin Cancer Res; 2016 Aug; 22(15):3831-40. PubMed ID: 26933125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer.
    Rogers TM; Arnau GM; Ryland GL; Huang S; Lira ME; Emmanuel Y; Perez OD; Irwin D; Fellowes AP; Wong SQ; Fox SB
    Sci Rep; 2017 Feb; 7():42259. PubMed ID: 28181564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel ALK fusion partners in lung cancer.
    Iyevleva AG; Raskin GA; Tiurin VI; Sokolenko AP; Mitiushkina NV; Aleksakhina SN; Garifullina AR; Strelkova TN; Merkulov VO; Ivantsov AO; Kuligina ESh; Pozharisski KM; Togo AV; Imyanitov EN
    Cancer Lett; 2015 Jun; 362(1):116-21. PubMed ID: 25813404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.
    Davis LE; Nusser KD; Przybyl J; Pittsenbarger J; Hofmann NE; Varma S; Vennam S; Debiec-Rychter M; van de Rijn M; Davare MA
    Mol Cancer Res; 2019 Mar; 17(3):676-685. PubMed ID: 30518629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
    Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
    Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Targeted Therapy for Tumors with
    Kheder ES; Hong DS
    Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NRG1 fusions in breast cancer.
    Howarth KD; Mirza T; Cooke SL; Chin SF; Pole JC; Turro E; Eldridge MD; Garcia RM; Rueda OM; Boursnell C; Abraham JE; Caldas C; Edwards PAW
    Breast Cancer Res; 2021 Jan; 23(1):3. PubMed ID: 33413557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.
    Solomon B; Varella-Garcia M; Camidge DR
    J Thorac Oncol; 2009 Dec; 4(12):1450-4. PubMed ID: 20009909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinase domain activation through gene rearrangement in multiple myeloma.
    Morgan GJ; He J; Tytarenko R; Patel P; Stephens OW; Zhong S; Deshpande S; Bauer M; Weinhold N; Schinke C; Rasche L; Bailey M; Ali S; Ross J; Miller VA; Stephens P; Thanendrarajan S; Zangari M; van Rhee F; Mughal T; Davies FE; Walker BA
    Leukemia; 2018 Nov; 32(11):2435-2444. PubMed ID: 29654269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of
    Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
    Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
    Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.